Drug targeting is a kind of phenomenon in which drug gets distributed in the body in such a manner that the drug interacts with the target tissue at a cellular or subcellular level to achieve a desired therapeutic response at a desire site without undesirable interactions at other sites. This can be achieved by modern methods of targeting the drug delivery system such as niosomes. Niosomes are the type of non-ionic surfactant vesicles, which are biodegradable, non-toxic, more stable and inexpensive, a new approach to liposomes. Their structure similar to liposome and hence they can represent alternative vesicular systems with respect to liposomes. The niosomes have the tendency to load different type of drugs. This review article represents the structure of niosome, advantages, disadvantages, the methods for niosome preparation and characterization of pharmaceutical NSVs.
INTRODUCTION
Drug targeting can be defined as the ability to direct a therapeutic agent at the desired site of action with little or no interaction with other tissue. Controlled drug delivery system is designed to obtain a desirable drug release profile for a longer period of time. There are various techniques to obtain controlled release system, one of them is niosomes. Niosomes are non-ionic surfactant vesicles with microscopic lamellar bilayer structure formed by self association of hydrated surfactant monomers. The multilamellar or unilamellar structure of niosomes is formed by mixing non-ionic surfactant, cholesterol and diethyl ether along with subsequent hydration in aqueous media 1 .
Niosomes are microscopic lamellar structures of the size range between 10 to1000 nm. The niosome consists of non-immunogenic, biodegradable and biocompatible surfactants. Niosomes are better than liposomes and its higher chemical stability of surfactants than phospholipids which are easily hydrolyzed due to the ester bond and cost effective 2 .
The application of vesicular (lipid vesicles and nonionic surfactant vesicles) systems in cosmetics and for therapeutic response may offer several advantages are-1) Higher patient compliance in comparison with oily dosage forms.
2) The vesicles may act as a depot, releasing the drug in a controlled manner.
3) Accommodate drug molecules with a wide range of solubilities Two components use in niosome preparation are  Cholesterol
 Non-ionic surfactants
A. Cholesterol is a steroid derivative, which is used to provide rigidity and proper shape, conformation to niosome form.
B.
Non-ionic Surfactants are generally used for the preparation of niosomes.
Examples: a. Tweens (20, 40, 60, 80) b. Spans (Span 60, 40, 20, 85, 80) c. Brijs (Brij 30, 35, 52, 58, 72, 76). 
DIFFERENT TYPES OF NON-IONIC SURFACTANTS

TYPES OF NIOSOMES
The various types of niosomes are as:
ii) Large unilamellar vesicles (LUV),
iii) Small unilamellar vesicles (SUV). 
Ether Injection Method -
Niosomes by slowly introduce in a solution of surfactant dissolve in diethyl ether into warm water maintain at 60 C Mixture in ether is injected through 14-gauge needle into an aqueous solution of material Vaporization of ether leads to the formation of the single layer vesicles
Diameter of the vesicle range from 50 to 1000 nm depends upon the conditions use 9,10 .
Reverse Phase Evaporation
Technique -Cholesterol and surfactant (ratio of 1:1) dissolves in the mixture of organic solvent (ether and chloroform). Addition of the aqueous drug solution to this and water in oil emulsion is formed; two phases are sonicated at 4-5ºC. The emulsion is dried in a rotary evaporator at 40°C to form a semisolid gel of large vesicles. Small amounts of phosphate buffered saline (PBS) are added to the clear gel and sonicate again. The organic phase is removed at 40ºC and lower pressure. Viscous niosomal suspension is further diluted with phosphate buffered saline, then heat on a water bath at 60ºC for 10 min to form niosomes 11.
The "Bubble" Method
Bubbling unit involves round-bottomed flask with three neck position in water bath to control the temperature Water-cool reflux is positioned in the first neck and thermometer is positioned in the second neck and nitrogen supply through the third neck
Cholesterol and surfactant are dispersed in the buffer (pH 7.4) at 70°C
Dispersion mixing for 15 seconds with high shear homogenizer "Bubbled" at 70°C using nitrogen gas 12 . 
Hand Shaking Method (Thin Film Hydration Technique/Rotary Evaporator) -
The mixing ingredients -surfactant and cholesterol and charge inducer Dissolves in a volatile organic solvent (chloroform, diethyl ether or methanol) in a round bottom flask By using a rotary evaporator organic solvent is evaporated at room temperature 20°C
Forming a thin layer of solid mixture
The dry surfactant film can be re-hydrated with an aqueous phase at 0-60°C with gentle agitation Formation of niosomes 13 . 
Multiple Membrane Extrusion
Ethanol Injection Method
An ethanol solution of surfactant is injected rapidly through a fine needle
Into excess of saline or other aqueous medium
Vaporization of ethanol
Formation of vesicles 15.
Micro Fluidization -
In this technique the principle involves is submerged jet principle in which two fluidized streams interact with each other at ultra high velocities and in the micro channels within the interaction chamber. Thin liquid sheet impingements along with common front are arranged such as that the energy supplies remain same within the area of niosomes formation, formation of niosomal vesicles of greater uniformity, smaller size and better reproducibility 16. B. Active Trapping Techniques -This includes the loading of the drug after the formation of niosomes. The niosomes are prepared and then the drug is load of maintaining a pH gradient or ion gradients to facilitate uptake of drug into niosomes. Various advantages of noisome form are 100% entrapment, high drug lipid ratios, absence of leakage, cost effectiveness and suitability for labile drugs.
Trans Membrane pH Gradient Drug Uptake Process
In remote loading process surfactants and cholesterol are dissolved in organic solvent (chloroform)
Solvent evaporates under reduced pressure to get a thin film on the wall of the round bottom flask 
Heating Method:
This method is in one-step, scalable and non-toxic and also based on the patent procedure. A suitable aqueous medium such as buffer distilled water, etc. in which mixtures of non-ionic surfactants, cholesterol and/or charge inducing molecules are added in the presence of the polyol like as glycerol. The mixture is heated with (at low shear forces) until the vesicles were form 19 .
Formation of Niosomes from Proniosomes:
Proniosome is a dry formulation in which each watersoluble particle are covered with a thin film of dry surfactant. The niosomes are recognizing by the adding aqueous phase at T > Tm with brief agitation. T is the Temperature and Tm is the mean phase transition temperature 20 .
Carrier + surfactant = proniosomes, Proniosomes + water = niosomes.
Lipid Injection Method:
This method does not require expensive organic phase. Mixture of lipids and surfactant is first melted and then injected into a highly agitate heated aqueous phase contains the dissolved drug. Drug dissolves in molten lipid and the mixture will be injected into agitate, heat aqueous phase containing surfactant.
FACTORS INFLUENCING NIOSOMAL FORMULATION:
21-25 Eg: span 60 with higher TC exhibits better entrapment.
The HLB value of surfactants ranging between 14 and 17 are not suitable for niosomal preparations. Decrease in the HLB value of surfactants from 8.6 to 1.7 decreases the entrapment efficiency and highest entrapment efficiency is found with the HLB value of 8.6.
Nature of Encapsulated Drug:
The charge and the rigidity of the niosomal bilayer are greatly influenced by physical chemical properties of the encapsulated drug. Entrapment of drug occurs by interacting with the surfactant head groups leading to the increasing charge and creates mutual repulsion of the surfactant bilayer and thus increases the vesicle size. The HLB of drug influences the degree of entrapment.
Hydration Temperature:
The size and shape of the niosome are affected by the temperature of hydration. Hydration temperature should be above the gel, liquid phase transition temperature. Change in temperature affects the assembly of surfactants into vesicles and vesicle shape modification. Hydration time and volume of hydration medium also accounts for the modification. Improper selection of the hydration temperature, time and hydration medium volume produces fragile niosomes / drug leakage problems may arise.
Cholesterol Content: Incorporation of cholesterol increases the entrapment efficiency and hydro-dynamic diameter of niosomes. Cholesterol acts in two ways:
 Increases the chain order of liquid state bilayers.
 Decreases the chain order of gel state bilayers.
An increase in the cholesterol concentration causes an increase in the rigidity of the bilayers and decrease in the release rate of encapsulated material. In hypotonic solution, inhibition of eluting fluid from vesicles results in the slow release initially followed by the faster release due to the mechanical loosening of vesicle structure under osmotic stress. 26, 27, 28 The removal of unentrapped solute from the vesicles can be accomplished by various techniques, which include: -
SEPARATION OF UNENTRAPPED DRUG
1) Dialysis:
The aqueous niosomal dispersion is dialyzed in dialysis tubing against phosphate buffer or normal saline or glucose solution.
2) Gel Filtration:
The unentrapped drug is removed by gel filtration of niosomal dispersion through a Sephadex-G-50 column and elution with phosphate buffered saline or normal saline.
3) Centrifugation:
The niosomal suspension is centrifuged and the supernatant is separated. The pellet is washed and then resuspended to obtain a niosomal suspension free from unentrapped drug.
CHARACTERIZATION OF NIOSOMES 29-35
Bilayer Rigidity and Homogeneity:
The biodistribution and biodegradation of niosomes are influenced by rigidity of the bilayer. In homogeneity can occur both within niosome structures and between niosomes in dispersion and could be identified via. p-NMR, Differential scanning calorimetry (DSC) and Fourier transform-infra red spectroscopy (FT-IR) techniques.
Size and Shape:
Various methods is used for the determination of mean diameter like as laser light scattering method besides it also determines by electron microscopy, molecular sieve chromatography, photon correlation microscopy, optical microscopy.
Stability Study:
Niosomal formulations are subject to stability studies by storing at 4°C, 25°C and 37°C in thermostatic oven for the period of three months. After one month, drug content of all the formulations are checked by entrapping efficiency parameter.
In-vitro Release:
In-vitro release rate study carried out by the use of 
a. Dialysis Tubing:
A dialysis sac is washed with distilled water. The prepared vesicle suspension is pipetted into a bag made up of the tubing dialysis and after that the bag is sealed. Then the bag containing the vesicles is placed in 200 ml of buffer solution in a 250 ml beaker with constant shaking at 25°C. At various time intervals, the buffer is an analysis of the drug content of an appropriate assay method.
b. Reverse Dialysis:
A number of small dialysis as containing 1ml of dissolution medium is placed in proniosomes. The proniosomes are then displaced into the dissolution medium. The direct dilution of the proniosomes is possible with this method and the rapid release cannot be quantified by using this method.
c. Franz Diffusion Cell:
The in vitro diffusion studies can be performed by using Franz diffusion cell. Proniosomes is placed in the donor chamber of a Franz diffusion cell fitted with cellophane membrane. The proniosomes is then dialyzed against a suitable dissolution medium at room temperature; the samples are withdrawn from the medium at suitable intervals and analyze for drug content using suitable method such as U.V spectroscopy, HPLC, etc. the maintenance of sink condition is essential.
Scanning Electron Microscopy:
The niosomes were observed under a scanning electron microscope (SEM) (JSM 6100 JEOL, Tokyo, Japan). They were mounted directly onto the SEM sample stub using double sided sticking tape and coated with gold film of thickness of 200 nm under reduced pressure of 0.001 mmHg.
Photographs were taken at suitable magnification.
Vesicle Charge:
The vesicle surface charge can play an important role in the behavior of niosomes in vivo and in vitro. Charged niosomes are more stable against aggregation and fusion then unchanged vesicles. In order to obtain an estimate of the surface potential, the zeta potential of individual niosomes can be measured by microelectrophoresis. An alternative approach is the use of pH-sensitive fluorophores. More recently, dynamic light scattering have been used to measure the zeta potential of niosomes.
Niosomal Drug Loading and Encapsulation Efficiency :
To determine drug loading and encapsulation efficiency, the niosomal aqueous suspension was ultracentrifuged, supernatant was removed and sediment was washed twice with distilled water in order to remove the adsorb drug.
 The niosomal recovery can be calculated as:
 The entrapment efficiency (EE) was then calculated using formula:
 The drug loading was calculated as: 
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NATURE OF DRUG AND ITS EFFECT ON STABILITY
APPLICATIONS OF NIOSOMES
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The application of niosomal technology is widely varied and can be used to treat a number of diseases.
Niosomes as Drug Carriers -
Niosomes have also been used as carriers for iobitridol, a diagnostic agent used for X-ray imaging.
Targeting of Bioactive Agents a. To Reticulo-Endothelial System (RES) -
The cells of the RES preferentially take up the vesicles. The uptake of niosomes by the cells is also by circulating serum factors known as opsonins, which mark them for clearance. Such localized drug accumulation has, however, been exploited in the treatment of animal tumors known to metastasize to the liver and spleen and in parasitic infestation of the liver.
b. To Organs, Other than RES -Carrier system can be directed to specific sites in the body by the use of antibodies . Immunoglobulins seem to bind quite readily to the lipid surface, thus offering a convenient means for targeting of drug carrier. Many cells possess the intrinsic ability to recognize and bind particular carbohydrate determinants and this can be exploited to the direct carriers system to particular cells.
3. Anti-neoplastic Treatment -Most antineoplastic drugs cause severe side effects. Niosomes can alter the metabolism prolong the circulation and half life of the drug, decreasing the side effects of the drugs. Niosomes decrease the rate of proliferation of tumor and higher plasma levels by slower elimination.
4.
Leishmaniasis -Leishmaniasis is a disease in which a parasite of the genus Leishmania invades the cells of the liver and spleen. Niosomes use in tests, conduct and shows that it was possible to administer higher levels of the drug without the triggering of the side effects, allows greater efficacy in the treatment.
Delivery of Peptide Drugs -
Use of niosomes to successfully protect the peptides from gastrointestinal peptide breakdown is being investigated. In an in-vitro study conducts by oral delivery of a vasopressin entrap derivative in niosomes shows that entrapment of the drug increases the stability of the peptide. 
Use in Studying Immune
ROUTE OF APPLICATION OF NIOSOMAL DRUG
FUTURE PROSPECTS
Niosomes represent a promising drug delivery molecule.
There is a lot of scope to encapsulate toxic anti-cancer drugs, anti-infective drugs, anti-AIDS drugs, antiinflammatory drugs, anti-viral drugs, etc. in niosomes and to use them as promising drug carriers to achieve better bioavailability and targeting properties and for reducing the toxicity and side-effects of the drugs. The ionic drug carriers are relatively toxic and unsuitable whereas niosomal carriers are safer. Handling and storage of niosomes require no special conditions.
